Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Maitland, G. Bakris, H. Black, Helen Chen, J. Durand, W. Elliott, S. Ivy, C. Leier, J. Lindenfeld, Glenn Liu, S. Remick, R. Steingart, W. Tang (2010)Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
JNCI Journal of the National Cancer Institute, 102
L. Lemmens, V. Claes, M. Uzzell (2008)Managing patients with metastatic colorectal cancer on bevacizumab.
British journal of nursing, 17 15
S. Tejpar, H. Piessevaux, K. Claes, P. Piront, J. Hoenderop, C. Verslype, E. Cutsem (2007)Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
The Lancet. Oncology, 8 5
A. Arnau, J. Ruiz, E. Rodrigo, J. Quintanar, M. Arias (2011)Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?
Transplantation proceedings, 43 6
A. Weidemann, W. Bernhardt, B. Klanke, C. Daniel, B. Buchholz, V. Câmpean, K. Amann, C. Warnecke, M. Wiesener, K. Eckardt, C. Willam (2008)HIF activation protects from acute kidney injury.
Journal of the American Society of Nephrology : JASN, 19 3
E. Berman, M. Nicolaides, R. Maki, M. Fleisher, S. Chanel, K. Scheu, Bri-Anne Wilson, G. Heller, N. Sauter (2006)Altered bone and mineral metabolism in patients receiving imatinib mesylate.
The New England journal of medicine, 354 19
ML Maitland, GL Bakris, HR Black, HX Chen, JB Durand, WJ Elliott (2010)Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
J Natl Cancer Inst, 102
W. Qi, F. Lin, Yuan‐jue Sun, Lina Tang, Aina He, Yang Yao, Zan Shen (2013)Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Cancer Chemotherapy and Pharmacology, 71
S. Ozkurt, G. Temiz, M. Açıkalın, M. Soydan (2010)Acute Renal Failure under Dasatinib Therapy
Renal Failure, 32
J. Usui, I. Glezerman, S. Salvatore, C. Chandran, C. Flombaum, S. Seshan (2014)Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Human pathology, 45 9
Yen-Ting Lin, Yu-Fen Wang, J. Yang, Chong-Jen Yu, Shang-Gin Wu, J. Shih, Pan‐Chyr Yang (2014)Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology, 9
H. Izzedine, C. Massard, J. Spano, F. Goldwasser, D. Khayat, J. Soria (2010)VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
European journal of cancer, 46 2
B. Kaplan, Y. Qazi, J. Wellen (2014)Strategies for the management of adverse events associated with mTOR inhibitors.
Transplantation reviews, 28 3
D. Murdoch, G. Forrest, D. Davies, G. Mcinnes (1993)A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects.
British journal of clinical pharmacology, 35 4
G. Quamme (1997)Renal magnesium handling: new insights in understanding old problems.
Kidney international, 52 5
C Uthurriague, S Thellier, D Ribes, L Rostaing, C Paul, N Meyer (2014)Vemurafenib significantly decreases glomerular filtration rate
J Eur Acad Dermatol Venereol JEADV, 28
M. Oroszlán, Michael Bieri, Nathalie Ligeti, A. Farkas, B. Meier, H. Marti, P. Mohacsi (2010)Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway.
Transplant immunology, 23 3
V. Eremina, M. Sood, J. Haigh, A. Nagy, G. Lajoie, N. Ferrara, H. Gerber, Y. Kikkawa, J. Miner, S. Quaggin (2003)Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.
The Journal of clinical investigation, 111 5
Yan Li, Shun Li, Yaofeng Zhu, Xinyue Liang, Hui Meng, Jun Chen, Dongqing Zhang, Hu Guo, B. Shi (2014)Incidence and Risk of Sorafenib‐Induced Hypertension: A Systematic Review and Meta‐Analysis
The Journal of Clinical Hypertension, 16
D. Cinà, T. Onay, A. Paltoo, Chengjin Li, Y. Maezawa, J. Arteaga, A. Jurisicova, S. Quaggin (2012)Inhibition of MTOR disrupts autophagic flux in podocytes.
Journal of the American Society of Nephrology : JASN, 23 3
A. Zou, A. Cowley (1999)Role of nitric oxide in the control of renal function and salt sensitivity
Current Hypertension Reports, 1
K. Bergethon, A. Shaw, S. Ou, Ryohei Katayama, C. Lovly, Nerina McDonald, P. Massion, C. Siwak-Tapp, Adriana Gonzalez, Rong Fang, E. Mark, Julie Batten, Haiquan Chen, K. Wilner, E. Kwak, J. Clark, D. Carbone, H. Ji, J. Engelman, M. Mino‐Kenudson, W. Pao, A. Iafrate (2012)ROS1 rearrangements define a unique molecular class of lung cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 8
Sandra Blanco, J. Bonet, D. López, I. Casas, R. Romero (2005)ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.
Kidney international. Supplement, 93
F. Gurevich, M. Perazella (2009)Renal effects of anti-angiogenesis therapy: update for the internist.
The American journal of medicine, 122 4
H. Izzedine, V. Gueutin, C. Gharbi, C. Mateus, C. Robert, É. Routier, Marina Thomas, A. Baumelou, P. Rouvier (2014)Kidney injuries related to ipilimumab
Investigational New Drugs, 32
W. Qi, Aina He, Zan Shen, Yang Yao (2013)Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
British journal of clinical pharmacology, 76 3
Michael Wang, S. Rule, P. Martin, A. Goy, R. Auer, B. Kahl, W. Jurczak, R. Advani, J. Romaguera, Michael Williams, J. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W. Jędrzejczak, Peter Johnson, S. Spurgeon, Lei Li, L. Zhang, K. Newberry, Z. Ou, N. Cheng, B. Fang, J. Mcgreivy, F. Clow, J. Buggy, B. Chang, D. Beaupre, L. Kunkel, K. Blum (2013)Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
The New England journal of medicine, 369 6
S. Klempner, Golnaz Aubin, A. Dash, S. Ou (2014)Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.
The oncologist, 19 9
V. Launay-Vacher, S. Zimner-Rapuch, N. Poulalhon, T. Fraisse, V. Garrigue, M. Gosselin, S. Amet, N. Janus, G. Deray (2014)Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients
H. Hurwitz, P. Douglas, J. Middleton, G. Sledge, David Johnson, D. Reardon, Dafeng Chen, O. Rosen (2013)Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
The oncologist, 18 3
Milena Marcolino, E. Boersma, N. Clementino, A. Macedo, A. Marx-Neto, Maria Silva, T. Gelder, K. Akkerhuis, A. Ribeiro (2011)Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 9
A. Shaw, Dong-Wan Kim, R. Mehra, D. Tan, E. Felip, L. Chow, D. Camidge, J. Vansteenkiste, Sunil Sharma, T. Pas, Gregory Riely, B. Solomon, J. Wolf, Michael Thomas, M. Schuler, Geoffrey Liu, A. Santoro, Yvonne Lau, M. Goldwasser, A. Boral, J. Engelman (2014)Ceritinib in ALK-rearranged non-small-cell lung cancer.
The New England journal of medicine, 370 13
G. Demetri, Patricia Russo, I. Macpherson, Ding Wang, J. Morgan, T. Evans, Morgan Ja, Demetri G, Wang D, Ludwig Center, Dana Farber (2009)Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 15
W. Groenestege, S. Thébault, J. Wijst, Dennis Berg, Rob Janssen, S. Tejpar, L. Heuvel, E. Cutsem, J. Hoenderop, N. Knoers, R. Bindels (2007)Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.
The Journal of clinical investigation, 117 8
F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi, S. Barni (2012)Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
Expert Opinion on Drug Safety, 11
Guobing Li, Chang-yu Shan, Lei Liu, Ting Zhou, Jing Zhou, Xiao-ye Hu, Yibiao Chen, H. Cui, N. Gao (2015)Tanshinone IIA Inhibits HIF-1α and VEGF Expression in Breast Cancer Cells via mTOR/p70S6K/RPS6/4E-BP1 Signaling Pathway
PLoS ONE, 10
P. Maliakal, Andrea Ledford (2010)Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study.
Experimental and therapeutic medicine, 1 2
W. Liang, M. Kujawski, Jun Wu, Jianming Lu, A. Herrmann, S. Loera, Y. Yen, F. Lee, Hua Yu, W. Wen, R. Jove (2010)Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor Microenvironment
Clinical Cancer Research, 16
K. Lute, K. May, Ping Lu, Huiming Zhang, E. Kocak, B. Mosinger, C. Wolford, G. Phillips, M. Caligiuri, P. Zheng, Yang Liu (2005)Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Blood, 106 9
J. Hood, C. Meininger, M. Ziche, H. Granger (1998)VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.
American journal of physiology. Heart and circulatory physiology, 274 3
S. Hiremath, D. Fergusson, Steve Doucette, A. Mulay, Gregory Knoll (2007)Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence
American Journal of Transplantation, 7
J. Folkman (1971)Tumor angiogenesis: therapeutic implications.
The New England journal of medicine, 285 21
H. Izzedine, J. Soria, B. Escudier (2013)Proteinuria and VEGF-targeted therapies: an underestimated toxicity?
Journal of nephrology, 26 5
V. Eremina, J. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. Kopp, M. Kabir, P. Backx, H. Gerber, N. Ferrara, L. Barisoni, C. Alpers, S. Quaggin (2008)VEGF inhibition and renal thrombotic microangiopathy.
The New England journal of medicine, 358 11
M. Fakih (2008)Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.
Oncology, 22 1
J. Rudge, J. Holash, D. Hylton, M. Russell, Shelly Jiang, Raymond Leidich, N. Papadopoulos, Erica Pyles, A. Torri, S. Wiegand, G. Thurston, N. Stahl, G. Yancopoulos (2007)VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
Proceedings of the National Academy of Sciences, 104
F. González-Pacheco, J. Deudero, M. Castellanos, M. Castilla, M. Alvarez-Arroyo, S. Yagüe, C. Caramelo (2006)Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2.
American journal of physiology. Heart and circulatory physiology, 291 3
H. Gerullis, L. Bergmann, L. Maute, Christoph Eimer, T. Otto (2009)Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany
Cancer Chemotherapy and Pharmacology, 63
F. Feihl, L. Liaudet, B. Waeber, B. Lévy (2006)Hypertension: a disease of the microcirculation?
Hypertension, 48 6
C. Vigneau, Nolwenn Lorcy, T. Dolley-Hitze, F. Jouan, Y. Arlot-Bonnemains, B. Laguerre, G. Verhoest, J. Goujon, M. Belaud‐Rotureau, N. Rioux-Leclercq (2014)All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29 2
E. Agabiti-Rosei (2003)[Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].
Drugs, 63 Spec No 1
G. Kaiafa, N. Kakaletsis, C. Savopoulos, V. Perifanis, A. Giannouli, N. Papadopoulos, S. Zisekas, A. Hatzitolios (2014)Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report
Journal of Clinical Pharmacy and Therapeutics, 39
Shigeo Horie, Munehide Kano, Kazuki Kawabe, Y. Mikami, A. Okubo, K. Nutahara, Eiji Higashihara (1994)Mediation of renal cyst formation by hepatocyte growth factor
The Lancet, 344
V. Kwitkowski, Tatiana Prowell, A. Ibrahim, A. Farrell, R. Justice, Shane Mitchell, R. Sridhara, R. Pazdur (2010)FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
The oncologist, 15 4
Enrico Agabiti-Rosei (2003)Modifications structurelles et fonctionnelles de la microcirculation dans l’hypertension: Influence du traitement pharmacologique
Nina Grenon (2013)Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.
Clinical journal of oncology nursing, 17 4
M. Fakih, G. Wilding, J. Lombardo (2006)Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Clinical colorectal cancer, 6 2
Xiaolei Zhu, K. Stergiopoulos, Shenhong Wu (2009)Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Acta Oncologica, 48
A. Pande, J. Lombardo, E. Spangenthal, M. Javle (2007)Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
Anticancer research, 27 5B
J. Yang, Leah Haworth, R. Sherry, P. Hwu, D. Schwartzentruber, S. Topalian, S. Steinberg, Helen Chen, S. Rosenberg (2003)A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
The New England journal of medicine, 349 5
M. Pou, N. Saval, M. Vera, A. Saurina, M. Solé, F. Cervantes, A. Botey (2003)Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
Leukemia & Lymphoma, 44
O. Hamnvik, T. Choueiri, A. Turchin, R. McKay, L. Goyal, Michael Davis, M. Kaymakcalan, Jonathan Williams (2015)Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
S. Holstein, J. Stokes, R. Hohl (2009)Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Leukemia research, 33 2
Xiaolei Zhu, Shenhong Wu, W. Dahut, C. Parikh (2007)Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 49 2
E. Wallace, W. Lyndon, P. Chumley, E. Jaimes, Huma Fatima (2013)Dasatinib-induced nephrotic-range proteinuria.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61 6
T. Kamba, Betty Tam, H. Hashizume, A. Haskell, B. Sennino, M. Mancuso, S. Norberg, S. O’Brien, Rachel Davis, L. Gowen, K. Anderson, G. Thurston, S. Joho, M. Springer, C. Kuo, D. McDonald (2006)VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.
American journal of physiology. Heart and circulatory physiology, 290 2
E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M. Bélair, J. Haymann, C. Legendre, L. Baud (2008)Sirolimus interacts with pathways essential for podocyte integrity.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24 2
J. Foringer, R. Verani, Vincent Tjia, Kevin Finkel, J. Samuels, Jayarama Guntupalli (2005)Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer
Annals of Pharmacotherapy, 39
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine, 363 8
Taichi Isobe, K. Uchino, Chinatsu Makiyama, H. Ariyama, S. Arita, S. Tamura, M. Komoda, H. Kusaba, T. Shirakawa, T. Esaki, K. Mitsugi, S. Takaishi, K. Akashi, E. Baba (2014)Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.
Anticancer research, 34 4
N. Shah, C. Tran, F. Lee, Ping Chen, Derek Norris, C. Sawyers (2004)Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
A. Gafter-Gvili, R. Ram, U. Gafter, O. Shpilberg, P. Raanani (2010)Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Leukemia research, 34 1
H. Sugimoto, Y. Hamano, D. Charytan, D. Cosgrove, M. Kieran, A. Sudhakar, R. Kalluri (2003)Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*
The Journal of Biological Chemistry, 278
Shenhong Wu, John Chen, A. Kudelka, Janice Lu, Xiaolei Zhu (2008)Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
The Lancet. Oncology, 9 2
T. Voets, B. Nilius, S. Hoefs, A. Kemp, G. Droogmans, R. Bindels, J. Hoenderop (2004)TRPM6 Forms the Mg2+ Influx Channel Involved in Intestinal and Renal Mg2+ Absorption*
Journal of Biological Chemistry, 279
M. Steinberg (2007)Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Clinical therapeutics, 29 11
J. Alemán, A. Farooki, M. Girotra (2014)Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.
Endocrine-related cancer, 21 3
H. Izzedine, S. Ederhy, F. Goldwasser, J. Soria, G. Milano, A. Cohen, D. Khayat, J. Spano (2009)Management of hypertension in angiogenesis inhibitor-treated patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 5
J. Vuky, C. Isacson, Mehran Fotoohi, J. Cruz, H. Otero, V. Picozzi, T. Malpass, D. Aboulafia, A. Jacobs (2006)Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma
Investigational New Drugs, 24
A. Blanchard, R. Vargas-Poussou, M. Vallet, A. Caumont-Prim, J. Allard, É. Desport, L. Dubourg, M. Monge, D. Bergerot, S. Baron, M. Essig, F. Bridoux, I. Tack, M. Azizi (2015)Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome.
Journal of the American Society of Nephrology : JASN, 26 2
R. Whang, L. Welt (1963)Observations in experimental magnesium depletion.
The Journal of clinical investigation, 42
P. Schnell, C. Bartlett, B. Solomon, V. Tassell, A. Shaw, T. Pas, Soo-Hyun Lee, G. Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, K. Wilner, A. Safferman, Ji-Youn Han (2015)Complex renal cysts associated with crizotinib treatment
Cancer Medicine, 4
H. François, P. Coppo, J. Hayman, B. Fouqueray, B. Mougenot, P. Ronco (2008)Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 51 2
R. Harper, M. Moore, M. Marr, L. Watts, P. Hutchins (1978)Arteriolar rarefaction in the conjunctiva of human essential hypertensives.
Microvascular research, 16 3
S. Bhaumik, V. Kher, P. Arora, P. Rai, M. Singhal, Amit Gupta, Ritesh Pandey, Raj Sharma (1996)Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis.
Renal failure, 18 1
Yun-fei Cao, Lidan Liu, C. Liao, A. Tan, F. Gao (2010)Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer
Cancer Chemotherapy and Pharmacology, 66
C. Uthurriague, S. Thellier, D. Ribes, L. Rostaing, Carle Paul, N. Meyer (2014)Vemurafenib significantly decreases glomerular filtration rate
Journal of the European Academy of Dermatology and Venereology, 28
F. Fadel, K. Karoui, B. Knebelmann (2009)Anti-CTLA4 antibody-induced lupus nephritis.
The New England journal of medicine, 361 2
H. Izzedine, O. Rixe, B. Billemont, A. Baumelou, G. Deray (2007)Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 50 2
Sheila Thomas, J. Brugge (1997)Cellular functions regulated by Src family kinases.
Annual review of cell and developmental biology, 13
A. Kirsch, V. Riegelbauer, A. Tagwerker, M. Rudnicki, A. Rosenkranz, K. Eller (2012)The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response.
American journal of physiology. Renal physiology, 303 4
E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon, Robert Maki, Sai-Hong Ou, Bruce Dezube, P. Jänne, Daniel, B. Costa, M. Varella-Garcia, W. Kim, Thomas Lynch, P. Fidias, Hannah Stubbs, J. Engelman, V. Lecia, Sequist, Weiwei Tan, L. Gandhi, M. Mino‐Kenudson, Greg Wei, S. Shreeve, M. Ratain, Jeffrey, Settleman, James Christensen, D. Haber, K. Wilner, R. Salgia, Geoffrey Shapiro, J. Clark, A. Iafrate (2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
The New England journal of medicine, 363 18
S. O'Sullivan, A. Horne, D. Wattie, F. Porteous, K. Callon, G. Gamble, P. Ebeling, P. Browett, A. Grey (2009)Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
The Journal of clinical endocrinology and metabolism, 94 4
R. Giusti, M. Cohen, P. Keegan, R. Pazdur (2009)FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
The oncologist, 14 3
Mikiko Takikita-Suzuki, M. Haneda, M. Sasahara, M. Owada, T. Nakagawa, M. Isono, S. Takikita, D. Koya, K. Ogasawara, R. Kikkawa (2003)Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury.
The American journal of pathology, 163 1
With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.
Targeted Oncology – Springer Journals
Published: Apr 30, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.